Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3326MR)

This product GTTS-WQ3326MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3326MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13970MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN3470-3471-3479
GTTS-WQ11013MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MCLA-117
GTTS-WQ7144MR IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FG-3019
GTTS-WQ8211MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA hLIV22
GTTS-WQ3068MR IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA Anti-TFPI
GTTS-WQ2750MR IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG162
GTTS-WQ9484MR IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA IPH-5401
GTTS-WQ10160MR IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LBR-101
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW